Phasing out anthracyclines in breast cancer: Is it time?


July 14, 2009

HemOnc today

For decades, anthracyclines have been the gold standard of treatment for women with breast cancer, but that could be changing...

Kevin R. Fox, MD, medical director of the Rena Rowan Breast Center at the University of Pennsylvania’s Abramson Cancer Center, said the percentage of breast cancer patients at his center assigned to anthracyclines has dropped from 100% five years ago to about 20% today. With a few qualifications, he said, he is convinced that some patients can be treated effectively without anthracyclines... Read More